Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.

Friess, T; Scheuer, W; Hasmann, M

Friess, T; Scheuer, W; Hasmann, M.

Affiliation

Friess T; Roche Diagnostics GmbH, Pharma Research Penzberg, Department of Pharmacology TR-PD2, Nonnenwald 2, D-82372 Penzberg, Germany. thomas.friess@roche.com

Anticancer Res ; 26(5A): 3505-12, 2006.

Article in En | MEDLINE | ID: mdl-17094474

Subject(s)

Carcinoma, Non-Small-Cell Lung/drug therapy; Disease Models, Animal; ErbB Receptors/metabolism; Lung Neoplasms/drug therapy; Protein Kinase Inhibitors/therapeutic use; Quinazolines/therapeutic use; Receptor, ErbB-2/metabolism; Animals; Antineoplastic Agents/therapeutic use; Carcinoma, Non-Small-Cell Lung/metabolism; Carcinoma, Non-Small-Cell Lung/pathology; ErbB Receptors/antagonists & inhibitors; Erlotinib Hydrochloride; Humans; Lung Neoplasms/metabolism; Lung Neoplasms/pathology; Mice; Mice, Inbred BALB C; Mice, Nude; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Carcinoma, Non-Small-Cell Lung / Receptor, ErbB-2 / Protein Kinase Inhibitors / Disease Models, Animal / ErbB Receptors / Lung Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Animals / Humans Language: En Journal: Anticancer Res Year: 2006 Type: Article Affiliation country: Germany

Search on Google

XML

PubMed Links